Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDM-05 is a preclinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics for the treatment of cardiometabolic diseases. It is part of a broader pipeline of RNAi therapies designed to leverage the company's proprietary delivery platforms, which enable targeted delivery to various tissues including the liver, adipose tissue, heart, kidneys, and the central nervous system. As an siRNA, SRNDM-05 functions by inducing the degradation of specific messenger RNA (mRNA) transcripts, thereby silencing the expression of a target protein associated with cardiometabolic dysfunction. The specific molecular target for SRNDM-05 has not yet been disclosed by the company.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRNDM-05.